810662-38-5 Usage
General Description
2-bromo-1-(4-(4-methyl-1H-imidazol-1-yl)phenyl)ethanone is an organic compound with the molecular formula C11H12BrN3O. It is a white solid that is sparingly soluble in water. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It has potential applications in the field of medicinal chemistry, specifically in the development of drugs targeting specific biological pathways. 2-bromo-1-(4-(4-methyl-1Himidazol-1-yl)phenyl)ethanone is also used in research and development, as well as in the manufacturing of various chemicals and materials. Additionally, it is important to handle this chemical with caution, as it may pose health hazards and should be used and stored in accordance with appropriate safety guidelines.
Check Digit Verification of cas no
The CAS Registry Mumber 810662-38-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,1,0,6,6 and 2 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 810662-38:
(8*8)+(7*1)+(6*0)+(5*6)+(4*6)+(3*2)+(2*3)+(1*8)=145
145 % 10 = 5
So 810662-38-5 is a valid CAS Registry Number.
810662-38-5Relevant articles and documents
Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators
Barnes, Keith D.,Buckle, Ronald N.,Chen, Xinchao,Herr, R. Jason,Johnson, Graham,Lin, Juinn H.,Mayhew, Nicholas J.,Mobley, William C.,Nguyen, Phuong,Paquette, William D.,Rynearson, Kevin D.,Sakwa, Samuel A.,Tanzi, Rudolph E.,Wagner, Steven L.,Yang, Jinhai
, (2020/09/22)
The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of Aβ42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting Aβ42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced Aβ42 levels in the plasma of J20 mice, in addition to reducing Aβ42 levels in the plasma and brain of Tg2576 mice.
